<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405989</url>
  </required_header>
  <id_info>
    <org_study_id>150-CL-037</org_study_id>
    <secondary_id>2009-015761-32</secondary_id>
    <nct_id>NCT01405989</nct_id>
  </id_info>
  <brief_title>To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)</brief_title>
  <official_title>An Open-label, Randomized, Two-period Crossover Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Pharmacokinetics of Darexaban and Metabolites in Young Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the effect of ketoconazole on the blood
      concentrations of darexaban and its metabolites (drug degradation products). The secondary
      objective of the study is to evaluate the safety and tolerability of a single dose of
      darexaban alone and when administered together with ketoconazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, 2-period crossover study in young healthy male subjects to evaluate
      the effect of multiple once daily doses of ketoconazole on the pharmacokinetics (PK) of
      darexaban and metabolites after a single dose of darexaban. In addition, safety and
      tolerability of darexaban administered alone and in combination with ketoconazole, is
      evaluated. Eligible subjects are admitted to the clinical unit in the morning of Day -1. The
      subjects are randomized to receive either first darexaban plus ketaconazole and then
      darexaban alone, or first darexaban alone followed by darexaban plus ketoconazole.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of darexaban and its metabolites assessed by plasma concentration</measure>
    <time_frame>Plasma samples are taken until 72 hours (darexaban alone) or 144 hours (combination of darexaban and ketoconazole) after darexaban dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG), clinical safety laboratory and adverse events</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Pharmacokinetics of Darexaban and Metabolites</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darexaban, wash-out, ketoconazole + darexaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketoconazole + darexaban, wash-out, darexaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darexaban</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_label>Treatment arm B</arm_group_label>
    <other_name>YM150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_label>Treatment arm B</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 18.5-30.0 kg/m2

          -  Male subjects must be non-fertile, i.e. surgically sterilized or must practice an
             adequate contraceptive method to prevent pregnancies

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to darexaban or ketoconazole or any components of
             the formulation used

          -  Any of the liver function tests (i.e. ALT, AST and bilirubin) above the upper limit of
             normal at repeated measures

          -  Any clinically significant history of any other disease or disorder -
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,
             dermatological, psychiatric or metabolic as judged by the medical investigator

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural and
             herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the
             Clinical Unit, except for occasional use of paracetamol (up to 3 g/day)

          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the
             3 months prior to admission to the Clinical Unit

          -  Donation of blood or blood products within 3 months prior to admission to the Clinical
             Unit

          -  Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or
             more than 21 units (210 g) of alcohol per week within the 3 months prior to study

          -  Participation in any clinical study within 3 months or participation in more than 3
             clinical studies within 12 months, prior to the expected date of enrolment into the
             study, provided that the clinical study did not entail a biological compound with a
             long terminal half life
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Aster, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=987</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <name_title>Disclosure Office Europe</name_title>
    <organization>Astellas Pharma Europe</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>darexaban</keyword>
  <keyword>ketoconazole</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Darexaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

